dysgeusia/karcinóm prsníka

Odkaz sa uloží do schránky

Vyberte typ zoradenia

Strana 1 od 24 výsledky

Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Distortion of taste sensations is a common chemotherapy-induced side effect; however, treatment evidence is limited. Pilot data indicated that acupuncture might be able to improve symptoms of dysgeusia. Thus, the aim of this study is to investigate the effects and side effects of

Awareness of dysgeusia and gustatory tests in patients undergoing chemotherapy for breast cancer.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE We analyzed the prevalence of gustatory test abnormalities in breast cancer (BC) patients undergoing chemotherapy. METHODS We enrolled 43 BC patients undergoing chemotherapy and 38 BC patients who had never undergone chemotherapy (control group). Two gustatory tests were conducted: an

Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The present study was a proof-of-concept study to provide an initial indication of the efficacy and safety of imaging malignant breast tumors using (99m)Tc-NC100692. The agent is a small peptide with high affinity for integrin receptors that are upregulated and expressed preferentially on

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND Evidence on adjuvant chemotherapy in older women with breast cancer is poor. We tested whether weekly docetaxel is more effective than standard chemotherapy. METHODS We carried out a multicenter, randomized phase III study. Women aged 65-79, operated for breast cancer, with average to

Comparison of Doctors' and Breast Cancer Patients' Perceptions of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

In Spain, around 26,000 cases of breast cancer are diagnosed each year, representing nearly 30% of all cancers in women. The aim this study was to compare the perceptions of nonhematologic toxicities after administration of a docetaxel, epirubicin, and cyclophosphamide (TEC) regimen between breast

Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND Docetaxel is a very active drug against breast cancer, but at the standard dose causes severe myelosuppression. In order to reduce the toxicity while maintaining the activity, weekly docetaxel administration was tested. METHODS We enrolled 30 patients with metastatic breast cancer, who

[Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The purpose of our study was to test the efficacy and toxicity of everolimus plus exemestane therapy for breast cancer. Between 2014 and 2015, 20 patients diagnosed with breast carcinoma were selected for this retrospective study. Patients received everolimus plus exemestane. As a result, 4 patients

[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

In a phase 3, double-blind, randomized, international study (the BOLERO-2), the addition of mTOR inhibitor everolimus to exemestane was evaluated in postmenopausal women with estrogen-receptor-positive (ER⁺) advanced/recurrent breast cancer that was refractory to any nonsteroidal aromatase inhibitor

Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Pathological complete response (pCR) is rare in hormone receptor-positive (HR+) HER2-negative breast cancer (BC) treated with either endocrine therapy (ET) or chemotherapy. Radical resection of locoregional relapse, although potentially curative in some cases, is challenging when the

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Within an ongoing multicentre phase 3 randomised trial (ELDA, cancertrials.gov ID: NCT00331097), early breast cancer patients, 65-79 years old, with average to high risk of recurrence, are randomly assigned to receive CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2,

[A case of recurrent breast cancer successfully treated with docetaxel].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

A 53-year-old female underwent mastectomy for left breast cancer in April, 1993. She was given oral tamoxifen but this had to be discontinued due to its side effects. In March, 1998, she developed bone and lung metastases, in spite of treatment with combination chemotherapy (CEF). We thus treated

Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Background and objectives: Chemotherapy does not only affect cancer cells; it also affects, to a greater or lesser degree, all other cells in the body. This toxicity should be assessed according to its severity, frequency, and duration,

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC. METHODS Patients received oral

Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE The objectives are to compare responses of breast cancer (BCa) treatment groups (chemotherapy, tamoxifen, and aromatase inhibitors (AIs) to each other and a control regarding (a) subjective oral health, (b) oral health-related behaviors, (c) oral health-related concerns, and (d)

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in

Predchádzajúce
1
2
Ďalšie

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume